(TVTX) Travere Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.930m USD | Total Return: 183% in 12m
Avg Turnover: 86.3M
Qual. Beats: 0
Rev. Trend: 93.4%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -3.6 is critical
Altman Z'' -9.63 < 1.0 - financial distress zone
Tailwinds
Supp Ema20, Leader, Confidence
Travere Therapeutics, Inc. (TVTX) is a commercial-stage biopharmaceutical company focused on rare kidney and metabolic diseases. Its primary revenue drivers include FILSPARI for IgA Nephropathy and Thiola for cystinuria. The company’s pipeline features late-stage candidates like sparsentan for focal segmental glomerulosclerosis and pegtibatinase for classical homocystinuria.
Operating in the orphan drug sector, the company benefits from regulatory incentives such as market exclusivity and tax credits designed to offset the high costs of developing treatments for small patient populations. The business model relies on a specialized sales force to navigate the complex reimbursement landscape associated with high-cost therapies for chronic genetic conditions.
Further analysis of the companys valuation metrics is available on ValueRay.
- Filspari commercial adoption and insurance coverage expansion drive primary revenue growth
- FDA decision on full approval for sparsentan dictates long-term market access
- Pegtibatinase clinical trial results determine pipeline diversification and valuation upside
- Generic competition for Thiola impacts legacy cash flow and operational funding
- Strategic pivot to rare kidney disease focus reduces overall research and development expenses
| Net Income: -21.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 42.96 > 1.0 |
| NWC/Revenue: 49.84% < 20% (prev 70.09%; Δ -20.25% < -1%) |
| CFO/TA 0.07 > 3% & CFO 39.6m > Net Income -21.4m |
| Net Debt (78.6m) to EBITDA (36.0m): 2.18 < 3 |
| Current Ratio: 3.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (91.9m) vs 12m ago 3.98% < -2% |
| Gross Margin: 93.95% > 18% (prev 0.92%; Δ 9.30k% > 0.5%) |
| Asset Turnover: 97.14% > 50% (prev 49.84%; Δ 47.30% > 0%) |
| Interest Coverage Ratio: -3.64 > 6 (EBITDA TTM 36.0m / Interest Expense TTM 10.2m) |
| A: 0.48 (Total Current Assets 392.7m - Total Current Liabilities 125.4m) / Total Assets 555.2m |
| B: -2.72 (Retained Earnings -1.51b / Total Assets 555.2m) |
| C: -0.07 (EBIT TTM -37.1m / Avg Total Assets 552.0m) |
| D: -3.31 (Book Value of Equity -1.51b / Total Liabilities 456.5m) |
| Altman-Z'' = -9.63 = D |
| DSRI: 1.30 (Receivables 87.3m/34.4m, Revenue 536.2m/273.5m) |
| GMI: 0.98 (GM 93.95% / 92.23%) |
| AQI: 0.94 (AQ_t 0.27 / AQ_t-1 0.29) |
| SGI: 1.96 (Revenue 536.2m / 273.5m) |
| TATA: -0.11 (NI -21.4m - CFO 39.6m) / TA 555.2m) |
| Beneish M = -2.26 (Cap -4..+1) = BBB |
As of May 24, 2026, the stock is trading at USD 44.74 with a total of 1,324,525 shares traded.
Over the past week, the price has changed by +4.32%,
over one month by +10.83%,
over three months by +44.58% and
over the past year by +182.99%.
Travere Therapeutics has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy TVTX.
- StrongBuy: 11
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 53.6 | 19.7% |
P/S = 7.3292
P/B = 39.8051
Revenue TTM = 536.2m USD
EBIT TTM = -37.1m USD
EBITDA TTM = 36.0m USD
Long Term Debt = 312.1m USD (from longTermDebt, last quarter)
Short Term Debt = 6.02m USD (from shortTermDebt, last quarter)
Debt = 343.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 15.6m
Net Debt = 78.6m USD (calculated: Debt 343.2m - CCE 264.7m)
Enterprise Value = 4.01b USD (3.93b + Debt 343.2m - CCE 264.7m)
Interest Coverage Ratio = -3.64 (Ebit TTM -37.1m / Interest Expense TTM 10.2m)
EV/FCF = 74.08x (Enterprise Value 4.01b / FCF TTM 54.1m)
FCF Yield = 1.35% (FCF TTM 54.1m / Enterprise Value 4.01b)
FCF Margin = 10.09% (FCF TTM 54.1m / Revenue TTM 536.2m)
Net Margin = -4.00% (Net Income TTM -21.4m / Revenue TTM 536.2m)
Gross Margin = 93.95% ((Revenue TTM 536.2m - Cost of Revenue TTM 32.4m) / Revenue TTM)
Gross Margin QoQ = 78.96% (prev none%)
Tobins Q-Ratio = 7.22 (Enterprise Value 4.01b / Total Assets 555.2m)
Interest Expense / Debt = 2.97% (Interest Expense 10.2m / Debt 343.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -29.3m (EBIT -37.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.84 (Total Current Assets 392.7m / Total Current Liabilities 138.3m)
Debt / Equity = 3.48 (Debt 343.2m / totalStockholderEquity, last quarter 98.7m)
Debt / EBITDA = 2.18 (Net Debt 78.6m / EBITDA 36.0m)
Debt / FCF = 1.45 (Net Debt 78.6m / FCF TTM 54.1m)
Total Stockholder Equity = 80.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.88% (Net Income -21.4m / Total Assets 555.2m)
RoE = -1.35% (Net Income TTM -21.4m / Total Stockholder Equity 1.59b)
RoCE = -1.95% (EBIT -37.1m / Capital Employed (Equity 1.59b + L.T.Debt 312.1m))
RoIC = -17.13% (negative operating profit) (NOPAT -29.3m / Invested Capital 171.1m)
WACC = 12.32% (E(3.93b)/V(4.27b) * Re(13.19%) + D(343.2m)/V(4.27b) * Rd(2.97%) * (1-Tc(0.21)))
Discount Rate = 13.19% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.11 | Cagr: 8.49%
[DCF] Terminal Value 62.86% ; FCFF base≈54.1m ; Y1≈54.3m ; Y5≈57.6m
[DCF] Fair Price = 4.90 (EV 534.7m - Net Debt 78.6m = Equity 456.1m / Shares 93.0m; r=12.32% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.30 | # QB: 0
Revenue Correlation: 93.41 | Revenue CAGR: 58.95% | SUE: -0.43 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.36 | Chg30d=+6.67% | Revisions=+11% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.55 | Chg30d=+5.05% | Revisions=+33% | Analysts=8
EPS current Year (2026-12-31): EPS=1.79 | Chg30d=+2.84% | Revisions=+40% | GrowthEPS=+96.8% | GrowthRev=+42.6%
EPS next Year (2027-12-31): EPS=5.01 | Chg30d=+8.49% | Revisions=+40% | GrowthEPS=+179.5% | GrowthRev=+39.3%
[Analyst] Revisions Ratio: +40%